In the report of Alencar et al.,14 the trend of prolonged PFS has been apparently improved in PB-DLBCL patients receiving rituximab-CHOP compared to those on a CHOP regime alone, but statistical significance (P = 0.062) was not reached. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.